We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Should Bivalirudin Replace Heparin During Percutaneous Coronary Interventions?
- Authors
Antman, Elliott M.
- Abstract
Editorial. Comments on the effectiveness of bivalirudin, a direct thrombin inhibitor, in treating patients undergoing a percutaneous coronary intervention (PCI). Discussion of a study by the investigators of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial, which suggests that clinicians should consider the drug as the core anticoagulent in treating PCI; Approval of bivalirudin by the U.S. Food & Drug Administration for use as an anticoagulent in patients with unstable angina undergoing percutaneous transluminal angioplasty; Comparison of bivalirudin to heparin.
- Subjects
UNITED States; ANTICOAGULANTS; HEPARIN; TRANSLUMINAL angioplasty; CARDIAC surgery; CLINICAL trials; DRUG efficacy
- Publication
JAMA: Journal of the American Medical Association, 2003, Vol 289, Issue 7, p903
- ISSN
0098-7484
- Publication type
Editorial
- DOI
10.1001/jama.289.7.903